Chunghwa Chemical Synthesis & Biotech Co Ltd (TW:1762) — Market Cap & Net Worth
Market Cap & Net Worth: Chunghwa Chemical Synthesis & Biotech Co Ltd (1762)
Chunghwa Chemical Synthesis & Biotech Co Ltd (TW:1762) has a market capitalization of $81.55 Million (NT$2.59 Billion) as of September 17, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #20070 globally and #1160 in its home market, demonstrating a -3.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chunghwa Chemical Synthesis & Biotech Co Ltd's stock price NT$33.65 by its total outstanding shares 76918000 (76.92 Million). Also see balance sheet size of Chunghwa Chemical Synthesis & Biotech Co for a full breakdown of the balance sheet.
Chunghwa Chemical Synthesis & Biotech Co Ltd Market Cap History: 2015 to 2026
Chunghwa Chemical Synthesis & Biotech Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $79.63 Million to $81.55 Million (1.87% CAGR). Also see 1762 cash flow metrics for how efficiently the company converts equity into cash flow.
Chunghwa Chemical Synthesis & Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chunghwa Chemical Synthesis & Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Chunghwa Chemical Synthesis & Biotech Co stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.07x
Chunghwa Chemical Synthesis & Biotech Co Ltd's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $57.23 Million | $1.20 Billion | $60.28 Million | 0.05x | 0.95x |
| 2017 | $52.73 Million | $1.17 Billion | $85.77 Million | 0.05x | 0.61x |
| 2018 | $50.27 Million | $1.02 Billion | $234.25 Million | 0.05x | 0.21x |
| 2019 | $80.86 Million | $1.16 Billion | $117.00 Million | 0.07x | 0.69x |
| 2020 | $142.17 Million | $1.54 Billion | $531.87 Million | 0.09x | 0.27x |
| 2021 | $153.69 Million | $1.93 Billion | $400.78 Million | 0.08x | 0.38x |
| 2022 | $158.97 Million | $2.12 Billion | $465.87 Million | 0.08x | 0.34x |
| 2023 | $139.10 Million | $2.09 Billion | $264.91 Million | 0.07x | 0.53x |
| 2024 | $82.15 Million | $1.35 Billion | $53.03 Million | 0.06x | 1.55x |
| 2025 | $59.37 Million | $804.88 Million | -$243.85 Million | 0.07x | N/A |
Competitor Companies of 1762 by Market Capitalization
Companies near Chunghwa Chemical Synthesis & Biotech Co Ltd in the global market cap rankings as of September 17, 2026. Review 1762 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Chunghwa Chemical Synthesis & Biotech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Chunghwa Chemical Synthesis & Biotech Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Chunghwa Chemical Synthesis & Biotech Co Ltd's market cap moved from $79.63 Million to $ 81.55 Million, with a yearly change of 1.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$81.55 Million | +37.35% |
| 2025 | NT$59.37 Million | -27.73% |
| 2024 | NT$82.15 Million | -40.94% |
| 2023 | NT$139.10 Million | -12.50% |
| 2022 | NT$158.97 Million | +3.44% |
| 2021 | NT$153.69 Million | +8.10% |
| 2020 | NT$142.17 Million | +75.81% |
| 2019 | NT$80.86 Million | +60.86% |
| 2018 | NT$50.27 Million | -4.67% |
| 2017 | NT$52.73 Million | -7.87% |
| 2016 | NT$57.23 Million | -28.12% |
| 2015 | NT$79.63 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Chunghwa Chemical Synthesis & Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $81.55 Million USD |
| MoneyControl | $81.55 Million USD |
| MarketWatch | $81.55 Million USD |
| marketcap.company | $81.55 Million USD |
| Reuters | $81.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chunghwa Chemical Synthesis & Biotech Co Ltd
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DM… Read more